GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (MIL:1MRNA) » Definitions » Inventories, Other

Moderna (MIL:1MRNA) Inventories, Other : €0 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Moderna Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Moderna's other inventories for the quarter that ended in Sep. 2024 was €0 Mil.

Moderna's quarterly other inventories declined from Mar. 2024 (€0 Mil) to Jun. 2024 (€-0 Mil) but then increased from Jun. 2024 (€-0 Mil) to Sep. 2024 (€0 Mil).

Moderna's annual other inventories declined from Dec. 2021 (€0 Mil) to Dec. 2022 (€0 Mil) but then stayed the same from Dec. 2022 (€0 Mil) to Dec. 2023 (€0 Mil).


Moderna Inventories, Other Historical Data

The historical data trend for Moderna's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Inventories, Other Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Other
Get a 7-Day Free Trial - - - - -

Moderna Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Moderna Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Moderna Business Description

Comparable Companies
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Headlines

No Headlines